CWC. M. Wiles

C. M. Wiles

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


C. M. Wiles has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical skills evaluation of trainees in a neurology department

    by Cm Wiles, K Dawson, Tat Hughes, Jg Llewelyn, Hr Morris, Tp Pickersgill, Np Robertson, Pem Smith

    Three to 12 evaluations of clinical performance using the mini-clinical evaluation exercise (Mini-CEX) (n=124) or direct observation of procedural skills (DOPS) (n=21) were performed on 27 trainees working in an NHS neurology department. The communications/counselling skills subdomain was scored in 64 evaluations. For Mini-CEX the focus was on gathering data (22%), diagnosis (31%), management (34%) and counselling (7%) (focus not recorded in 6%). For DOPS, lumbar puncture was the most common evaluated procedure (57%). Mini-CEX evaluations lasted 23.8 minutes (10.6) (mean, sd) and DOPS 25.9 minutes (12.6). MiniCEX scores for overall competence and communication skills were mean 5.99 (sd 0.95, range 4–8) and 5.98 (sd 1.21, range 3–9) and for DOPS 5.71 (sd 0.90, range 4–8) both on scales of 1 to 9. Overall trainee competence and communication scores increased with year of training (p<0.001, p<0.004 univariate analysis). Assessors undertook up to three or four assessments in a session. Assessors and trainees considered that the observation and feedback had been ‘very’ or ‘quite’ useful in providing a relevant element of assessment. These assessments were feasible and useful in a neurology department and provided some evidence for increasing performance with trainee seniority. More assessor time (approximately one hour) than trainee time (24–26 min) was needed for each assessment undertaken.


  • Open Access

    Mentoring Trainees in Neurology

    by C. M. Wiles


  • Open Access

    (undefined)

    by C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al.

    Treatment of neurological disorders with intravenous immunoglobulin (IVIg) is an increasing feature of our practice for an expanding range of indications. For some there is evidence of benefit from randomised controlled trials, whereas for others evidence is anecdotal. The relative rarity of some of the disorders means that good randomised control trials will be difficult to deliver. Meanwhile, the treatment is costly and pressure to “do something” in often distressing disorders considerable. This review follows a 1 day meeting of the authors in November 2000 and examines current evidence for the use of IVIg in neurological conditions and comments on mechanisms of action, delivery, safety and tolerability, and health economic issues. Evidence of efficacy has been classified into levels for healthcare interventions (tables 1 and 2).